Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

JCI Insight

Volumn 4, Issue 20, 2019, Pages

  Kulcsar, Kirsten A ^a   Coleman, Christopher M ^a   Beck, Sarah E ^b   Frieman, Matthew B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; CCL2 PROTEIN, MOUSE; CXCL10 PROTEIN, MOUSE; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; IMMUNE RESPONSE; LIPID DIET; MACROPHAGE; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; VIRUS PATHOGENESIS; VIRUS TITRATION; ADVERSE EVENT; ANIMAL; BLOOD; CORONAVIRUS INFECTION; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; METABOLISM; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; CHEMOKINE CXCL10; COMORBIDITY; CORONAVIRUS INFECTIONS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85078200507     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.131774     Document Type: Article

References (68)

1. Cotten M, et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerging Infect Dis. 2013;19(5):736-42B.
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization website. https://www.who.int/emergencies/mers-cov/en/. Updated 2019. Accessed October 1, 2019.
3. Cho SY, et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: An epidemiological outbreak study. Lancet. 2016;388(10048):994-1001.
4. Azhar EI, et al. Evidence for camel-To-human transmission of MERS coronavirus. N Engl J Med. 2014;370(26):2499-2505.
5. Haagmans BL, et al. Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation. Lancet Infect Dis. 2014;14(2):140-145.
6. Meyer B, et al. Time course of MERS-CoV infection and immunity in dromedary camels. Emerging Infect Dis. 2016;22(12):2171-2173.
7. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18(8):e217-e227.
8. Al-Tawfiq JA, Assiri A, Memish ZA. Middle East respiratory syndrome novel corona MERS-CoV infection. Epidemiology and outcome update. Saudi Med J. 2013;34(10):991-994.
9. Assiri A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis. 2013;13(9):752-761.
10. Ng DL, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652-658.
11. Alsaad KO, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516-524.
12. Ahmed AE. The predictors of 3-And 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis. 2017;17(1):615.
13. Matsuyama R, Nishiura H, Kutsuna S, Hayakawa K, Ohmagari N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): A systematic review and meta-Analysis. BMC Public Health. 2016;16(1):1203.
14. Rivers CM, Majumder MS, Lofgren ET. Risks of death and severe disease in patients with Middle East respiratory syndrome coronavirus, 2012-2015. Am J Epidemiol. 2016;184(6):460-464.
15. Yang YM, et al. Impact of comorbidity on fatality rate of patients with Middle East respiratory syndrome. Sci Rep. 2017;7(1):11307.
16. Choi WS, et al. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infect Chemother. 2016;48(2):118-126.
17. Alraddadi BM, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerging Infect Dis. 2016;22(1):49-55.
18. Al-Tawfiq JA, et al. Middle East respiratory syndrome coronavirus: A case-control study of hospitalized patients. Clin Infect Dis. 2014;59(2):160-165.
19. Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81-84.
20. Alqahtani FY, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: A retrospective study. Epidemiol Infect [published online ahead of print November 5, 2018]. 2018. doi: 10.1017/S0950268818002923.
21. Al-Tawfiq JA, Gautret P. Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: extent and implications for infection control: A systematic review. Travel Med Infect Dis. 2019;27:27-32.
22. Arwady MA, et al. Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014. Emerging Infect Dis. 2016;22(8):1395-1402.
23. Garbati MA, et al. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS ONE. 2016;11(11):e0165978.
24. Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol. 2015;83(5):401-408.
25. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. International Diabetes Federation website. http://www.diabetesatlas. org. Updated 2017. Accessed October 8, 2019.
26. Zmora N, Bashiardes S, Levy M, Elinav E. The role of the immune system in metabolic health and disease. Cell Metab. 2017;25(3):506-521.
27. McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-Associated metabolic disease. J Clin Invest. 2017;127(1):5-13.
28. Meshkani R, Vakili S. Tissue resident macrophages: Key players in the pathogenesis of type 2 diabetes and its complications. Clin Chim Acta. 2016;462:77-89.
29. Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-Associated inflammation. J Diabetes Res. 2017;2017(4):6494795-6494796.
30. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2015;144(2):171-185.
31. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-Type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol. 2014;95(Pt 2):408-412.
32. Lu G, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227-231.
33. Peck KM, Cockrell AS, Yount BL, Scobey T, Baric RS, Heise MT. Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J Virol. 2015;89(8):4696-4699.
34. Pascal KE, et al. Pre-And postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA. 2015;112(28):8738-8743.
35. Coleman CM, et al. CD8+ T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol. 2017;91(1):e01825-16.
36. Li K, et al. Mouse-Adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci USA. 2017;114(15):E3119-E3128.
37. Cockrell AS, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016;2:16226.
38. Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014;111(13):4970-4975.
39. Iwata-Yoshikawa N, et al. Acute respiratory infection in human dipeptidyl peptidase 4-Transgenic mice infected with Middle East respiratory syndrome coronavirus. J Virol. 2019;93(6):e01818-18.
40. Heydemann A. An overview of murine high fat diet as a model for type 2 diabetes mellitus. J Diabetes Res. 2016;2016:2902351.
41. Islam MS, Loots du T. Experimental rodent models of type 2 diabetes: A review. Methods Find Exp Clin Pharmacol. 2009;31(4):249-261.
42. Poissy J, et al. Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases. J Clin Virol. 2014;61(2):275-278.
43. Page C, et al. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol. 2012;86(24):13334-13349.
44. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:80.
45. Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: A review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21.
46. Berger JP, et al. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice. Endocrinol Diabetes Metab. 2018;1(1):e00002.
47. The Jackson Laboratory. Phenotype information for diet-induced obese C57Bl/6J. The Jackson Laboratory website. https://www. jax.org/jax-mice-And-services/strain-data-sheet-pages/phenotype-information-380050. Updated 2019. Accessed October 8, 2019.
48. Karlsson EA, Hertz T, Johnson C, Mehle A, Krammer F, Schultz-Cherry S. Obesity outweighs protection conferred by adjuvanted influenza vaccination. MBio. 2016;7(4):e01144-16.
49. Kosaraju R, et al. B cell activity is impaired in human and mouse obesity and is responsive to an essential fatty acid upon murine influenza infection. J Immunol. 2017;198(12):4738-4752.
50. O'Brien KB, et al. Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis. 2012;205(2):252-261.
51. Milner JJ, et al. Obesity increases mortality and modulates the lung metabolome during pandemic H1N1 influenza virus infection in mice. J Immunol. 2015;194(10):4846-4859.
52. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc. 2017;14(Suppl 5):S406-S409.
53. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-894.
54. Singer K, et al. Differences in hematopoietic stem cells contribute to sexually dimorphic inflammatory responses to high fat diet-induced obesity. J Biol Chem. 2015;290(21):13250-13262.
55. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues-The biology of pear shape. Biol Sex Differ. 2012;3(1):13.
56. Shin HS, et al. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin Infect Dis. 2019;68(6):984-992.
57. Zhao J, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017;2(14):eaan5393.
58. Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S. Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis. Immunology. 2015;144(4):677-686.
59. Cheung KP, Taylor KR, Jameson JM. Immunomodulation at epithelial sites by obesity and metabolic disease. Immunol Res. 2012;52(3):182-199.
60. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.
61. Maroof A, Yorgensen YM, Li Y, Evans JT. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014;10(1):e1003875.
62. McKinstry KK, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol. 2009;182(12):7353-7363.
63. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis. 2013;208(5):739-748.
64. Matsuzaki G, Umemura M. Interleukin-17 family cytokines in protective immunity against infections: role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s. Microbiol Immunol. 2018;62(1):1-13.
65. Alim MA, Sikder S, Bridson TL, Rush CM, Govan BL, Ketheesan N. Anti-mycobacterial function of macrophages is impaired in a diet induced model of type 2 diabetes. Tuberculosis (Edinb). 2017;102:47-54.
66. Hodgson KA, Morris JL, Feterl ML, Govan BL, Ketheesan N. Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect. 2011;13(14-15):1177-1184.
67. Williams NL, Morris JL, Rush C, Govan BL, Ketheesan N. Impact of streptozotocin-induced diabetes on functional responses of dendritic cells and macrophages towards Burkholderia pseudomallei. FEMS Immunol Med Microbiol. 2011;61(2):218-227.
68. Li K, et al. Mouse-Adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci USA. 2017;114(15):E3119-E3128.